Toll Free: 1-888-928-9744
Published: Apr, 2015 | Pages:
1449 | Publisher: RESEARCH IMPACT TECHNOLOGIES
Industry: Biotechnology | Report Format: Electronic (PDF)
This report on Angiogenesis Modulators & Therapeutics studies the impact of Inhibitors and Stimulators on various diseases. The study focuses on major angiogenesis inhibitors and their role in diseases such as cancer, cardiology, ophthalmology, and other angiogenesis based diseases including endometriosis and inflammatory diseases. The emphasis is also given on major angiogenesis stimulators and their role in diseases such as cardiovascular disorders including ischemia, congestive heart failure, coronary artery disease, myocardial infarction and peripheral vascular disease and chronic wound care. The study provides global market analysis for angiogenesis therapeutic products by the above angiogenesis modulators and also by the disease areas such as cancer, cardiovascular disorders and other angiogenesis based diseases. Compilation of Worldwide Patents and Research related to Angiogenesis is also provided. The study includes estimations and predictions for the total global angiogenesis therapeutic products market. Estimations and predictions are also graphically illustrated by geographic regions encompassing the North America, Europe, Asia-Pacific and Rest of World.
Table of Content 1. SCOPE AND METHODOLOGY 1 2. REPORT SYNOPSIS 3 2.1 Introduction 3 Angiogenesis 3 Exhibit 1. Segmentation of Global Angiogenesis Modulators Market by Angiogenesis Modulators and Therapeutic Area 3 Exhibit 2. Segmentation of Global Angiogenesis Therapeutic Products for Cancer Market by Type 3 Angiogenesis Modulators 4 Angiogenesis Inhibitors 4 Mode of Action 5 Blocking of VEGF Pathway 5 Angiogenesis Stimulators 5 Angiogenesis – Therapeutic Areas 6 Cancer 6 Cancer 6 Thalomid and lenalidomide (Revlimid) are some other drugs that are used in cancer therapy and these have affect on growth of blood vessels. These have affect on cancer in other ways as well. 6 Cardiovascular 6 Mechanical Therapy for Stimulating Angiogenesis 7 TMR 7 EECP 7 Ophthalmology 7 Other Diseases 8 Endometriosis 8 Rheumatology 8 Wound Healing 8 Dermatology 9 2.2 Angiogenesis Modulators - Global Market Analysis 10 Exhibit 3. Angiogenesis Modulators - Global Market Estimations & Predictions (2005 -2020) in US$ Million 10 Exhibit 4. List of Major Global Companies in Angiogenesis Modulators Market 11 3. MARKET DYNAMICS 12 3.1 Market Overview 12 Global Market Analysis 12 3.2 Global Angiogenesis Modulators Market 13 Exhibit 5. Angiogenesis Modulators - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 13 Exhibit 6. Angiogenesis Modulators – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 14 3.3 North American Angiogenesis Modulators Market 15 Exhibit 7. Angiogenesis Modulators – North American Market Estimations & Predictions (2005 - 2020) by Country for United States and Canada in US$ Million 15 Exhibit 8. Angiogenesis Modulators – North American Market Shares (2010, 2015 & 2020) by Country for United States and Canada 16 Exhibit 9. List of Major Companies in North America 16 3.3 (I) United States Angiogenesis Modulators Market 16 3.3 (II) Canadian Angiogenesis Modulators Market 16 Exhibit 10. List of Approved Angiogenesis based Drugs in the United States 17 3.4 European Angiogenesis Modulators Market 20 Exhibit 11. Angiogenesis Modulators - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe in US$ Million 20 Exhibit 12. Angiogenesis Modulators – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe 21 3.4 (I) German Angiogenesis Modulators Market 21 3.4 (II) UK Angiogenesis Modulators Market 21 3.4 (III) French Angiogenesis Modulators Market 21 3.4 (IV) Swiss Angiogenesis Modulators Market 21 3.4 (V) Russian Angiogenesis Modulators Market 21 Exhibit 13. List of Major European Companies in Angiogenesis Modulators Market 22 Exhibit 14. List of Approved Angiogenesis based Drugs in Europe 22 3.5 Asia-Pacific Angiogenesis Modulators Market 25 Exhibit 15. Angiogenesis Modulators - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, Australia, India and Rest of Asia-Pacific in US$ Million 25 Exhibit 16. Angiogenesis Modulators – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, Australia, India and Rest of Asia-Pacific 26 3.5 (I) Japanese Angiogenesis Modulators Market 26 3.5 (II) Chinese Angiogenesis Modulators Market 26 3.5 (III) Australian Angiogenesis Modulators Market 26 3.5 (IV) Indian Angiogenesis Modulators Market 26 Exhibit 17. List of Major Asia-Pacific Companies in Angiogenesis Modulators Market 26 3.6 Rest of World Angiogenesis Modulators Market 27 Exhibit 18. Angiogenesis Modulators - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Brazil, South Africa, Israel and Other Countries in US$ Million 27 Exhibit 19. Angiogenesis Modulators – Rest of World Market Shares (2010, 2015 & 2020) by Country for Brazil, South Africa, Israel and Other 28 3.6 (I) Brazilian Angiogenesis Modulators Market 28 3.6 (II) South African Angiogenesis Modulators Market 28 3.6 (III) Israeli Angiogenesis Modulators Market 28 3.7 Company Profiles - Major Players in Angiogenesis Market 29 Amgen, Inc. (USA) 29 AstraZeneca plc (UK) 29 Bayer Pharma AG (Germany) 30 Bionomics Ltd. (Australia) 32 CASI Pharmaceuticals, Inc. (USA) 33 Celgene Corporation (USA) 35 Eisai Co., Ltd. (Japan) 35 Eli Lilly and Company (USA) 37 F.Hoffmann-La Roche Ltd. (Switzerland) 37 Genentech, Inc. (USA) 38 GlaxoSmithKline plc (UK) 40 KCI Licensing, Inc. (USA) 41 Merck KGaA (Germany) 42 Novartis AG (Switzerland) 42 OHR Pharmaceuticals (USA) 45 Organogenesis, Inc. (USA) 45 Pfizer, Inc. (USA) 46 Progen Pharmaceuticals Ltd. (Australia) 47 Regeneron Pharmaceuticals, Inc. (USA) 48 Sanofi SA (France) 49 Silence Therapeutics plc (UK) 50 Smith & Nephew plc (UK) 51 Takeda Pharmaceutical Co., Ltd. (Japan) 52 Taxus Cardium Pharmaceuticals Group (USA) 53 Vical, Inc. (USA) 54 3.8 Major Activities in Angiogenesis Market 55 Bayer Yakuhin’s Aflibercept Receives Approval in Japan for Application in Myopic CNV Treatment 55 Antitope and UCL Enters into Collaboration for an Important Antibody 55 FDA Approves Avastin for Cervical Cancer 55 Indian-American Scientist to Launch Wound-Healing Products in India 56 Investigational Monoclonal Antibody OS2966 of OncoSynergy Granted Orphan Drug Status by the FDA to Treat Glioblastoma 56 US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 57 Nexavar® (sorafenib) Approved to Treat Differentiated Thyroid Cancer in Japan 57 Duke Cancer Institute, UNC and WUSTL Team Up to Accelerate Oncology Drug Development 58 US FDA Approves First Targeted Drug for Advanced Stomach Cancer 58 Effective New Peptide Developed to Treat Ulcer and Wound 59 TRACON and Santen Enters into Agreement to Develop and Commercialize TRC105 in Ophthalmology 59 Strategic Collaboration between Bayer & German Cancer Research Center (DKFZ) Against Cancer 59 Pfizer and Merck Enters into Collaboration to Study Innovative Anti-Cancer Combinations 60 Eddingpharm Acquires Worldwide Rights to Oncology Assets, Inclusive of Telatinib, from ACT Biotech 60 ARIAD Enters into Commercialization Agreement for Iclusig (Ponatinib) in Australia 61 Ethical Oncology Science (EOS) Acquired by Clovis Oncology; Obtains Rights to Lucitanib, a Unique Dual-Selective Phase II FGFR/VEGFR Inhibitor 61 Clovis Oncology to Partner with Servier 61 Avastin Receives Approval for Additional Indication of Ovarian Cancer 62 USPTO Issues Notice of Allowance to Patent Extensive Cancer Diagnostic Applications of MIR-21 62 MedImmune Acquires Amplimmune 62 BI Submits MAA for EU Approval of New Oncology Compound, Nintedanib 63 Servier and Shanghai Institute of Materia Medica Join Hands 63 AstraZeneca Teams Up with Cambridge Medical Research Institutions to Advance Cancer Research 64 ENMD Submits an Application for New Drug Global Clinical Trial for the Proprietary ENMD-2076 with CFDA of China 64 Avastin Receives Approval for Additional Indication of Malignant Glioma 64 Phase III Clinical Trial of Regorafenib Initiated 64 EntreMed Gains Patent for ENMD-2076 in China 65 Exelixis to Commence METEOR Clinical Trial for Cabozantinib in mRCC Patients 65 ArQule Recovers Global Rights to AKT Program 66 Exelixis Inks a 3-Year Supply Agreement with Sobi for the Distribution of COMETRIQ for MTC in the EU 66 Stivarga Receives FDA Approval for Metastatic GIST 66 Exelixis Markets COMETRIQ™ in the US 67 EntreMed Finalizes the Site for Phase 2 studies in TNBC 67 Genentech’s Avastin® with Chemotherapy Gain US FDA Approval for Application for mCRC Treatment 68 COMETRIQ™ Attains FDA Approval for Therapeutic Application in MTC 68 AnGes MG Receives Medical Use Patent for HGF in Japan 68 ArQule Along with Daiichi Sankyo Inks a SPA Agreement 69 Ethical Oncology Science Collaborates with Servier 69 Dyax Inks a Licensing Agreement with Kadmon 70 Abcam Acquires Epitomics, Known for RabMAb® Technology 70 AnGes and Mitsubishi Tanabe Pharma Enters into Agreement for Exclusive Marketing Rights of Collategene in the United States 70 BioInvent Enters into Oncology Collaboration with Cancer Research Technology 71 BioInvent Together with ThromboGenics to Acquire Complete Rights to TB-403 71 European Commission Accepts CAPRELSA (vandetanib) for Patients with Advanced Medullary Thyroid Cancer 71 Pfizer’s INLYTA® (Axitinib) Receives FDA Approval for Advanced Renal Cell Carcinoma (RCC) 72 BioLineRx Collaborates with Compugen to Enhance and Market the Innovative Drug Candidates of Compugen 72 Teva Merges with Cephalon 73 Bayer HealthCare Restructures Global Oncology Partnership with Onyx Pharmaceuticals to Settle Litigation 73 Lorus Therapeutics Receives Australian Patent for the Anti-Cancer Drug LOR-253 73 SuperGen Inc., Renamed as Astex Pharmaceuticals Inc., 74 Medical-Use Patent for Ets-1 in the US 74 SuperGen Acquires Astex Therapeutics 74 IBC Generium In-Licenses New Anti‐VEGF Antibody Drug from Affitech A/S 75 Capstone Therapeutics and BiolineRx Plans to Co-Develop a Chrysalin (TP508) based Drug 75 Quest Diagnostics Takes Over Celera 75 Abcam Acquires MitoSciences to Enhance Immunoassay Portfolio 75 Sanofi-Aventis Completely Acquires Genzyme Corporation 76 Alcon Completely Merges with Novartis, Creating a New Eye Care Division 76 Regulus Therapeutics and UC San Diego to utilize microRNA Technology in Angiogenic Disease Research Collaboration 76 Human Genome Sciences and Fiveprime Therapeutics Collaborates to Develop and Market New Anti-Cancer Drug 77 Arteriocyte Launches NANEX™ Stem Cell Expansion System 77 Hana Biosciences Renamed as Talon Therapeutics 77 Eyetech Initiates the Development of Extended Release Formulation of Macugen 78 Biotica Reports a Unique Molecular Target of Bioengineered Borrelidin Analogues 78 Ethical Oncology Science Initiates Phase I Clinical Trials of E-3810 78 Gilead Sciences Acquires CGI Pharmaceuticals for US$ 120 Million 79 Sanofi-Aventis Acquires TargeGen 79 FDA Approves Lucentis for Macular Edema following Retinal Vein Occlusion 79 Progen Pharmaceuticals and Medigen Biotech Corp., Enters into a License and Collaboration Agreement 80 ACT Biotech Obtains Orphan Drug Designation for Telatinib for Gastric Cancer 80 TRACON Initiates TRC 105 Antibody Therapy for Prostate Cancer 81 FDA Grants Orphan Drug Status to ENMD-2076 in Leukemia 81 Votrient Receives FDA Approval 81 PolyMedix Receives US Patent for Angiogenesis Inhibitor Compounds 81 Lilly Acquires ImClone Systems 82 FDA Grants Orphan Drug Status to VEGFb™ Intended to be Used Against Advanced Melanoma 82 Nexavar® First FDA-Approved Drug Therapy for Liver Cancer 82 Bionomics’ Anti-Cancer Compound Gains IND Approval 83 Bilateral Agreement for Product Distribution between Cell Culture Service and TCS Cellworks Limited 83 Coley Agrees to Acquisition by Pfizer 84 Chugai Achieves Japanese Regulatory Approval for Tarceva® for NSCLC Treatment 84 Synta Pharmaceuticals and GSK to Jointly Develop STA-4783 84 Atrium Biotechnologies Inc. will Become Atrium Innovations, Inc. 85 ARIAD Announces Collaboration with ICON Medical to Develop and Commercialize Novel Deforolimus-Eluting Stents 85 Bristol-Myers Squibb Acquires Adnexus Therapeutics 85 Celera Enters Oncology Research Collaboration with Merck to Develop Pharmacogenomic Tests 86 Avastin® and Chemotherapy Combination as First-line Treatment for NSCLC Approved in Europe 86 Genentech Acquires Tanox 87 System Medicine, Now a Wholly Owned Subsidiary of Cell Therapeutics, Inc 87 ARIAD and Merck & Co., Inc. Announce Global Collaboration to Jointly Develop and Commercialize AP23573 - ARIAD's Novel mTOR Inhibitor - for Cancer 87 Valentis and Urigen Merge 88 National Cancer Institute Selects SR 16388 of SRI International 88 Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology 88 Strategic Alliance Between Merck and Archemix 89 Progen Industries is now Progen Pharmaceuticals 89 Chugai Pharmaceutical Obtains Approval for Avastin® in Japan 89 Eisai Corporation Concludes the Deal to Acquire Morphotek, Inc 90 Celera and LabCorp® Announce Licensing Agreement to Commercialize Breast Cancer Testing Assays 90 Paradigm Therapeutics Acquired by Takeda Pharmaceutical 90 ARIAD Grants Second Commercial License to its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies 91 University of Bristol Awards Drug Discovery Contract to Galapagos NV 91 ImClone Systems Decides to Focus on its Proprietary Product, IMC-1121B 91 AngioGenetics Discovers New Mechanism for Blood Vessel Growth 92 Seattle Genetics in Exclusive Worldwide Licensing Agreement with Genentech for SGN-40 92 Celgene Acquires API Unit from Siegfried Ltd. 92 Otsuka and Chugai in Co-Promotion Deal 93 Merck Buys Entire Stake in Sirna Therapeutics 93 Genetix Acquires Applied Imaging Corporation 93 InterMune and Roche Close Collaboration Agreement 93 EntreMed Presents 2ME2 for Rheumatoid Arthritis 94 Genzyme Acquires AnorMED 94 Biomira Acquires ProlX Pharmaceuticals 94 Pfizer Acquires PowderMed 94 CTT Cancer Targeting Technologies and Karyon Ltd., Merge 94 LibraGen and Sanofi-Aventis in Partnership for Microbial Diversity Applications 94 Schering and Sonus Sign Global Licensing Agreement for TOCOSOL(R) Paclitaxel 95 Merck Acquires Serono 95 Sangamo Acquires Edwards' Angiogenesis Program 95 AstraZeneca Acquires Cambridge Antibody Technology 95 GSK and Shionogi Complete Initial Clinical Study for HIV Integrase Inhibitor 95 Cardium Acquires Wound Healing Technology and Related Assets of TRC 96 GSK and Galapagos Enter Into an Alliance for Osteoarthritis Drug Development 96 Caliper Acquires Xenogen 96 Pharmacopeia and Allergan Inc., in AMD Research Agreement 96 Angiotech Pharmaceuticals Acquires Quill Medical Inc. 96 Mayne Acquires SuperGen's North American Rights for Oncology Products 96 Erbitux ® Approved in the US 97 Corgentech Adopts New Name 97 Angiotech and Genzyme Enter Into Strategic Collaboration for Developing Oncology Treatments 97 Alcon and Amgen for Joint Development of Ophthalmology Therapies 97 CancerVax Merges with Micromet 97 Microbix and Angiogen Enter Into Marketing Agreement 97 SuperGen Acquires Montigen 98 Novartis Takes Over Chiron 98 Amgen Completes Acquisition of Abgenix 98 Æterna Zentaris’ Development of Cetrorelix to Continue in Japan 98 Corautus Genetics Puts Forth VEGF-2 Studies 98 Angiotech Pharmaceuticals Takes Over American Medical Instruments 99 Amgen and Biovitrum in License Agreement 99 Cryptome Takes Over HealthLinx 99 AngioGenex Merges with eClic 99 Merck Acquires Full US Rights to BLP25 Liposome Vaccine from Biomira 99 Human Genome Science and Amgen in Licensing Agreement 99 Protein Design Labs Changes Corporate Identity 100 Bausch & Lomb and PTC Therapeutics in Research Collaboration Deal 100 Sanofi-Aventis and Regeneron Pharmaceuticals Amend VEGF Collaboration 100 OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals 100 Hybridon Adopts New Name 100 Xencor and Centocor Enter into Monoclonal Antibodies Agreement 100 Corautus in Diabetic Neuropathy Licensing Agreement 101 Xantos and Cryptome Sign Agreement to Validate Cancer Leads 101 Xantos and Atugen Sign Collaboration Agreement 101 Allergan and Sanwa Kagaku Kenkyusho Develop Posurdex in Japan 101 Corautus and Boehringer Ingelheim Sign Agreement to Produce VEGF-2 101 Bayer and Onyx Announce Access to Sorafenib (BAY 43-9006) 102 7TM Signs Therapeutic Angiogenesis Research Agreement with P&G 102 Genzyme Acquires Verigen 102 Antisoma and Raylo Sign Agreement for Manufacturing AS1411 102 Alcon and Morphochem Enter Into Alliance for Ophthalmic Compounds 102 ImClone Systems Signs License Agreements 103 Pfizer Takes Over Angiosyn 103 3.9 Analysis by Modulators 104 Exhibit 20. Angiogenesis Modulators – Global Market Estimations & Predictions (2005 - 2020) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million 104 Exhibit 21. Angiogenesis Modulators – Global Market Shares (2010, 2015 & 2020) by Angiogenesis Modulators for Inhibitors and Stimulators 105 3.9.1 Angiogenesis Inhibitors 106 3.9.1.1 Global Angiogenesis Inhibitors Market 106 Exhibit 22. Angiogenesis Inhibitors - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 107 Exhibit 23. Angiogenesis Inhibitors – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 108 3.9.1.2 North American Angiogenesis Inhibitors Market 109 Exhibit 24. Angiogenesis Inhibitors – North American Market Estimations & Predictions (2005 - 2020) by Country for United States and Canada in US$ Million 109 Exhibit 25. Angiogenesis Inhibitors – North American Market Shares (2010, 2015 & 2020) by Country for United States and Canada 110 3.9.1.2 (I) United States Angiogenesis Inhibitors Market 110 3.9.1.2 (II) Canadian Angiogenesis Inhibitors Market 110 3.9.1.3 European Angiogenesis Inhibitors Market 111 Exhibit 26. Angiogenesis Inhibitors - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe in US$ Million 111 Exhibit 27. Angiogenesis Inhibitors – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe 112 3.9.1.3 (I) German Angiogenesis Inhibitors Market 112 3.9.1.3 (II) UK Angiogenesis Inhibitors Market 112 3.9.1.3 (III) French Angiogenesis Inhibitors Market 112 3.9.1.3 (IV) Swiss Angiogenesis Inhibitors Market 112 3.9.1.3 (V) Russia Angiogenesis Inhibitors Market 112 3.9.1.4 Asia-Pacific Angiogenesis Inhibitors Market 113 Exhibit 28. Angiogenesis Inhibitors - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, Australia, India and Rest of Asia-Pacific in US$ Million 113 Exhibit 29. Angiogenesis Inhibitors – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, Australia, India and Rest of Asia-Pacific 114 3.9.1.4 (I) Japanese Angiogenesis Inhibitors Market 114 3.9.1.4 (II) Chinese Angiogenesis Inhibitors Market 114 3.9.1.4 (III) Australian Angiogenesis Inhibitors Market 114 3.9.1.4 (IV) India Angiogenesis Inhibitors Market 114 3.9.5 Rest of World Angiogenesis Inhibitors Market 115 Exhibit 30. Angiogenesis Inhibitors - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Brazil, South Africa, Israel and Other Countries in US$ Million 115 Exhibit 31. Angiogenesis Inhibitors – Rest of World Market Shares (2010, 2015 & 2020) by Country for Brazil, South Africa, Israel and Other Countries 116 3.9.1.5 (I) Brazilian Angiogenesis Inhibitors Market 116 3.9.1.5 (II) South African Angiogenesis Inhibitors Market 116 3.9.1.5 (III) Israeli Angiogenesis Inhibitors Market 116 3.9.2 Angiogenesis Stimulators 117 3.9.2.1 Global Angiogenesis Stimulators Market 117 Exhibit 32. Angiogenesis Stimulators - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 118 Exhibit 33. Angiogenesis Stimulators – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 119 3.9.2.2 North American Angiogenesis Stimulators Market 120 Exhibit 34. Angiogenesis Stimulators – North American Market Estimations & Predictions (2005 - 2020) by Country for United States and Canada in US$ Million 120 Exhibit 35. Angiogenesis Stimulators – North American Market Shares (2010, 2015 & 2020) by Country for United States and Canada 121 3.9.2.2 (I) United States Angiogenesis Stimulators Market 121 3.9.2.2 (II) Canadian Angiogenesis Stimulators Market 121 3.9.2.3 European Angiogenesis Stimulators Market 122 Exhibit 36. Angiogenesis Stimulators - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe in US$ Million 122 Exhibit 37. Angiogenesis Stimulators – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe 123 3.9.2.3 (I) German Angiogenesis Stimulators Market 123 3.9.2.3 (II) UK Angiogenesis Stimulators Market 123 3.9.2.3 (III) French Angiogenesis Stimulators Market 123 3.9.2.3 (IV) Swiss Angiogenesis Stimulators Market 123 3.9.2.3 (V) Russian Angiogenesis Stimulators Market 123 3.9.2.4 Asia-Pacific Angiogenesis Stimulators Market 124 Exhibit 38. Angiogenesis Stimulators - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, Australia, India and Rest of Asia-Pacific in US$ Million 124 Exhibit 39. Angiogenesis Stimulators – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, Australia, India and Rest of Asia-Pacific 125 3.9.2.4 (I) Japanese Angiogenesis Stimulators Market 125 3.9.2.4 (II) Chinese Angiogenesis Stimulators Market 125 3.9.2.4 (III) Australian Angiogenesis Stimulators Market 125 3.9.2.4 (IV) Indian Angiogenesis Stimulators Market 125 3.9.2.5 Rest of World Angiogenesis Stimulators Market 126 Exhibit 40. Angiogenesis Stimulators - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Brazil, South Africa, Israel and Other in US$ Million 126 Exhibit 41. Angiogenesis Stimulators – Rest of World Market Shares (2010, 2015 & 2020) by Country for Brazil, South Africa, Israel and Other 127 3.9.2.5 (I) Brazilian Angiogenesis Stimulators Market 127 3.9.2.5 (II) South African Angiogenesis Stimulators Market 127 3.9.2.5 (III) Israeli Angiogenesis Stimulators Market 127 3.10 Analysis by Therapeutic Area 128 Exhibit 42. Angiogenesis Therapeutic Areas - Global Market Estimations & Predictions (2005 - 2020) for Cancer, Cardiovascular, Ophthalmology and Other in US$ Million 128 Exhibit 43. Angiogenesis Therapeutic Areas – Global Market Shares (2010, 2015 & 2020) for Cancer, Cardiovascular, Ophthalmology and Other 129 3.10.1 Cancer Angiogenesis Modulators 130 3.10.1.1 Global Cancer Angiogenesis Modulators Market 130 Exhibit 44. Cancer Angiogenesis Modulators – Global Value Market Estimations & Predictions (2005 - 2020) by Cancer Therapeutics for Lung Cancer, Colorectal Cancer, Breast Cancer and Other in US$ Million 130 Exhibit 45. Angiogenesis Modulators for Cancer – Global Value Market Shares (2010, 2015 & 2020) by Cancer Therapeutics for Lung Cancer, Colorectal Cancer, Breast Cancer and Other 131 Cancer 132 Exhibit 46. Angiogenesis Cancer - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 133 Exhibit 47. Angiogenesis Modulators for Cancer – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 134 3.10.1.1 (I) North American Cancer Angiogenesis Modulators Market 134 3.10.1.1 (II) European Cancer Angiogenesis Modulators Market 134 3.10.1.1 (III) Asia-Pacific Cancer Angiogenesis Modulators Market 134 3.10.1.1 (IV) Rest of World Cancer Angiogenesis Modulators Market 134 3.10.2 Cardiovascular Angiogenesis Modulators 135 3.10.2.1 Global Cardiovascular Angiogenesis Modulators Market 136 Exhibit 48. Angiogenesis Modulators for Cardiovascular Diseases - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 136 Exhibit 49. Angiogenesis Modulators for Cardiovascular Diseases – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 137 3.10.2.1 (I) North American Cardiovascular Angiogenesis Modulators Market 137 3.10.2.1 (II) European Cardiovascular Angiogenesis Modulators Market 137 3.10.2.1 (III) Asia-Pacific Cardiovascular Angiogenesis Modulators Market 137 3.10.2.1 (IV) Rest of World Cardiovascular Angiogenesis Modulators Market 137 3.10.3 Ophthalmology Angiogenesis Modulators 138 3.10.3.1 Global Ophthalmology Angiogenesis Modulators Market 139 Exhibit 50. Angiogenesis Modulators for Ophthalmology - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 139 Exhibit 51. Angiogenesis Modulators for Ophthalmology – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 140 3.10.3.1 (I) North American Ophthalmology Angiogenesis Modulators Market 140 3.10.3.1 (II) European Ophthalmology Angiogenesis Modulators Market 140 3.10.3.1 (III) Asia-Pacific Ophthalmology Angiogenesis Modulators Market 140 3.10.3.1 (IV) Rest of World Ophthalmology Angiogenesis Modulators Market 140 3.10.4 Angiogenesis Modulators for Other Diseases 141 3.10.4.1 Global Market for Angiogenesis Modulators for Other Diseases 141 Exhibit 52. Angiogenesis Modulators for Other Angiogenesis based Diseases - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 141 Exhibit 53. Angiogenesis Modulators for Other Angiogenesis based Diseases – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 142 3.11 Angiogenesis Modulators – Market Outlook 143 4. PRODUCT/TECHNOLOGY RESEARCH 144 4.1 Introduction 144 Angiogenesis – The Growth of New Blood Vessels 144 The Process 145 The Types 145 Sprouting Angiogenesis 145 Role of Angioprotien in Sprouting of Angiogenesis 146 Intussusceptive Angiogenesis 146 Role of Intussusceptive Angiogenesis in Embryonic Vascular Network Configuration 146 Therapeutic Angiogenesis 147 Role of Therapeutic Angiogenesis in Various Diseases 147 Delivery of Drugs in Cancer Therapy through Angiogenesis 148 Angiogenic Therapy for Heart 148 4.2 Modulators of Angiogenesis 148 Angiogenesis Inhibitors 149 Natural Angiogenesis Inhibitors 149 Angiostatin – A Potent Angiogenesis Inhibitor of Tumor Growth 149 Heparin Hexasaccharide Fragment 149 Interleukin-12 150 Placental Ribonuclease Inhibitor 150 Retinoids 151 Thrombospondin-1 (TSP-1) 151 Role of TSP-1 as Autocrine Negative Regulator for Human Dendritic Cell Activation 152 Cartilage Derived Inhibitor 152 Angioarrestin 152 Endostatin 153 Platelet Factor-4 153 Metalloproteinase Inhibitors 153 Interferon Alpha/Beta/Gamma 154 Other 154 Angiogenesis Stimulators 155 Natural Angiogenic Stimulators 155 Vascular Endothelial Growth Factor (VEGF) 155 VEGF Splice Variants and Their Functions 155 Role of VEGF in Various Diseases 155 Effect of VEGF & bFGF on In-vivo and In-vitro Conditions 156 Fibroblast Growth Factors 156 Basic FGF 157 Expression of bFGF (FGF2) in Various Diseases 157 Alzheimer's 157 Precursor Neural Cells of Mice 158 Acidic FGF 158 Role of aFGF in ADPKD 158 Expression of aFGF in Alzheimer's 159 Granulocyte Colony-Stimulating Factor (G-CSF) 159 Impact of G-CSF on Neutrophils 159 The Usage of G-CSF in Pharma Industry 159 Angiogenin 160 Angiopoietin-1 160 Platelet Derived Endothelial Cell Growth Factor 161 Uterine Cervical Cancers and Role of PD-ECGF 161 Leptin 161 Leptin’s MoA 162 Midkine 162 Placental Growth Factor 162 Stimulation of Inflammation and Swelling – Role of Placental Growth Factor 163 Hepatocyte Growth Factor (HGF)/Scatter Factor (SF) 163 Transforming Growth Factor (TGF) 164 TGFα 164 TGFβ 164 The TGFβ receptor 164 Other 164 4.3 Angiogenesis in Diseases 165 Remedy of Diseases with Angiogenesis Inhibitors 165 Angiogenesis Inhibitors-Patients Demographics 165 Exhibit 54. Angiogenesis Inhibitors - Global Market Estimations & Predictions (2005 -2020) of Patients Treated in Million 166 Cancer Therapy – Role of Angiogenesis 167 Global Market for Major Cancer Types 167 Exhibit 55. Global Market for Major Cancer Types (2010 & 2012) – Breast, Colorectal, Lung and Prostate in US$ Billion 167 Cancer Therapy Angiogenesis Vs Conventional 168 Conventional Cancer Treatments 168 Surgery 168 Radiation Therapy for Healing Cancer 168 Chemotherapy Treatment 169 Hormone Stimulation Therapy 169 Process of Immuno Therapy 169 Experimenting Phase 169 Targeted Therapy 170 Angiostatic Therapy 170 Angiostatic Agents 171 Angiolytic Photodynamic Therapy 172 Researches in Development of Cancer Therapy 173 Angiobalans 174 Global Cancer Demographics 175 Exhibit 56. Global Cancer Incidence – Estimated Incidence and Mortality for 2012 in Thousands 175 Alzheimer’s 175 Dermatology 176 Cosmetic Dermatology 176 Angiogenesis in Dermatology 176 Angiogenesis Inhibitors 176 Angiogenesis Stimulating Drugs 176 Psoriasis 176 Role of Angiogenesis in Psoriasis 177 Rosacea 177 MoA of Photoaging in Rosacea Pathogenesis 178 Ophthalmology 178 Age Related Macular Degeneration 178 Advanced stage of vision loss 178 Causes 179 Characteristics of the Disorder 179 Detection process of the Disorder 180 Medication 180 Precautionary measure 180 Types of AMD 181 Other Turmoil Based on Angiogenesis 181 Rubeosis Iridis 181 Neovascularization 181 Neovascularization in Association with Angiogenesis 182 Rheumatology 182 Rheumatoid Arthritis 182 Angiogenesis in Rheumatoid Arthritis – Pathogenic and Therapeutic Implications 183 Skin Related Ailments 183 Deficient Angiogenesis in Skin Diseases 183 Osteoarthritis (OA), Angiogenesis and Inflammation 184 Other 184 Inflammatory Diseases 184 Growth of New Blood Vessels in Inflammation 184 Cause of joint swelling due to inflammation 185 Endometriosis 186 Symptoms of the Disease 186 Wound Care – Role of Angiogenesis 187 Soluble Factors Responsible for Wound Angiogenesis 188 Diabetic Foot Ulcers 188 Angiogenesis in Cardiovascular Disorders 189 Ischemia 190 Role of ASK 1 in Angiogenesis during Ischemia 190 Role of NGF in Neo-Vascularization during Ischemic Conditions 190 Congestive Heart Failure 190 Root of CHF 191 Detection of CHF 191 Treatment of CHF 191 Role of Angiogenesis in CHF 192 Coronary Artery Disease 192 Angina 192 Heart Attack 192 Heart Failures 192 Arrhythmias 192 Symptoms Identified for CAD 193 Role of Angiogenesis in CAD Treatment 193 Peripheral Vascular Disease 193 Angiogenic Therapy for the Treatment of PVD 194 Peripheral Artery Disease 194 Therapeutic Angiogenesis in PAD 194 Myocardial Infarction 195 4.4 Angiogenesis Modulators - Research Briefs 196 Model of MicroRNAs in Liver Cancer for Studying Pathogenesis and New Therapeutic Methods 196 Doctors Develop Personalized Cancer Treatments with Help of Novel Research Technique 196 Work by a Bangalorean, May Make Bypass Outdated 197 Scientists Find a Natural Retinal Neovascular Mouse Prototype 198 Tumor Characteristic of Taking Control Over Brain's Blood Supply Could Help in Treatment 199 Protein Blocking Tumor Growth, found 201 Cutting Off Nutrients to Pancreatic Cancer Cells 201 Omega (ω)-3 Blocks Blood Vessel Growth in AMD 202 Scripps Research Institute Researchers Show Molecular ‘Yin-Yang’ of Blood Vessel Growth 203 Molecules Identified that Act in Rheumatoid Arthritis Angiogenesis 204 Presence of Marker May Predict Response to Ipilimumab in Advanced Melanoma 205 Combinatorial Drug Therapy for Triple-Negative Breast Cancer 206 Recent Variety Discovered Immune Cell that Enable Tumors to Grow 207 Methylation Signaling Regulates Cancer Growth 207 Ramucirumab Prolongs Longevity in Stomach cancer 208 Proteins Concerned with Spread of Brain Tumors Found 208 Novel MR Analysis Procedure Discloses Brain Tumor Reaction to Anti-angiogenesis Therapy 209 Molecule of Immune System Favors Tumor Resistance in Anti-angiogenic Therapy 210 New Target to Fight against Angiogenesis based Cancer 210 Synergistic Therapy for Ovarian Cancer 211 Latest Two-Drug Combination Aids Ovarian Cancer Treatment 212 Protein Concerned with ‘Bad’ Blood Vessel Growth Found 212 Genetic Variants Indicating Aggressive Prostate Cancers Found 213 Cholesterol May Cause Unregulated Growth of Blood Vessels 214 Study Reveals Enzyme’s Double Life and Its Important Part in Cancer Blood Supply 214 Fatty Acid Metabolite Found to be Useful to Fight Cancer in Mice 215 Drug Decreases Fats by Blocking Blood Vessels 216 Reprieve for Gynecological Disorders: An Injectable Protein That Could Undo Symptoms of Dangerous Conditions 217 Spread of Skin Cancer to Other Parts of the Body 218 Discovery of New Protein that Can Treat Damaged Bones 219 Investigation Provides New Targets for Stroke Therapy 219 Combination Therapy May Help Improve Chances of Survival of the Patients of Breast Cancer with Brain Metastases 220 Simvastatin, if Applied Topically Can Expedite Healing of Diabetic Wounds 221 New Blood –Vessel Generating Cell with Treatment Capacity 222 Double Drug Combination Could Close Down Abnormal Blood Vessel Proliferation that Encourages Disease 223 New Subtypes of Ovarian Cancer May be Susceptible to Anti-Angiogenic Drugs 224 PDGF-BB and EPO in Cancer Cause 225 Hydrogel Aids in Scar-Free Skin in Third-Degree Burn 226 Cell Molecule Identified as Central Player in the Formation of New Blood Vessels 227 Identification of Key Molecule Blocking Abnormal Blood Vessel Growth in Tumors 229 Dual-Action Protein Performance in Controlled Blood Vessel Formation 230 Novel Understanding into the Way Tumor Cells are Fed 231 Mechanism behind Cancer Growth by White Blood Cell Discovered 233 Blocking Receptor in Key Hormone Aids in Cancer Cell Death 234 Exorbitant Blood Vessels Leads to Alzheimer’s Disease 235 Gold Nanoparticles Help Scientists in Getting a Step Closer to Treatment for Cancer 237 Immune System Suppression Has Been Linked to Blood Vessel Formation in Tumors 238 Indirubin May Block Brain Tumor's Spread 239 New Molecular Imaging Agent for Detection of Angiogenesis 240 A New Imaging Agent for Detection of Breast Cancer 241 Regenerating Blood Vessels 241 Protein May be Able to Improve Recovery from Heart Attacks 242 Zoledronic Acid in the Treatment of Early Lung Cancer 243 DMP1 Protein May Lead to Cancer and Other Diseases 244 Protein That Diminishes Melanoma Tumor Growth, Discovered 244 Blocking Blood Vessels Two Times Leads to Tumor Starvation 245 ACE-041, Novel Target to Stop Tumor Blood Supply 245 nPT-bor Program – New Molecular Target 246 Enhancement in Radiation Therapy Discovered with New Targets for Available Drugs 246 New Anti-Angiogenesis Targets Discovered 247 EZH2 Aids in Creation of Blood Vessels for Ovarian Cancer 247 Cellular Mechanism and Blood Vessel Permeability 248 miR-132 and Uncontrolled Cell Growth 248 Advanced study shows Morphine’s Effectiveness on Blocking Tumor Growth 248 Gene Expression Targeting Angiogenesis 249 MR Imaging of Angiogenesis Using Nanosized Contrast Agents 249 Bone Marrow Cells Producing Nerve Growth Factors Promotes Angiogenesis 250 Angiogenesis can be Activated by the Cellular Mechanical Forces 251 Angiogenesis to be Monitored by HRGP 252 Blocking of EphB4 Obstructs Angiogenesis As Well As Tumor Growth 253 New Inhibitor of Tumor Angiogenesis 254 Obstructing Nuclear Receptor Cuts Off Tumor Blood Supply 254 New Target for Prospective Breakthrough in Cancer Treatment 255 Targeting of Cancerous Vessels 255 Probiotics Effective for Colitis Treatment 256 Mechanism Preventing Formation of Blood Vessels, Explained 256 Process of Metastasis in Prostate Cancer 256 Hearing Improved via Tumor Inducing Genetic Disorder Treatment 257 Discovery of SFRP2, a New Target to Aid in Potential Cancer Drug Development 258 Angiogenesis and Ovarian Cancer Drugs 258 Angiogenesis Inhibitor Enhances Brain Tumor Survival 259 New Compact Device for Restraining Production of Blood Vessels 260 Reducing Cholesterol May Reduce the Risk of Cancer 261 Novel Oral Therapy Aids in Lung Cancer Shrinking before Surgery 261 Angiogenesis Inhibitor Formulated Through Nanotechnology Shows Promising Anticancer Results 262 Anti-Cancer Synthetic Drug Candidate Targets Tumor Cell Growth and Angiogenesis 264 RGS5 Helps in Treating Tumors 264 Stem Cell Types a vital Constituent in Angiogenesis and Cancer Growth 265 Asthma Susceptibility Gene Causes Breathing Difficulties 266 Effect of Prokineticin 2/Bv8 on Human Hepatocellular Carcinoma 267 VEGF Family Protein Protect Nerve Cells from Death without Side Effects 268 Development of New Molecular Pathways which Demonstrate Development of New Blood Vessels 268 New Protein Drug Target Discovered, that Controls Blood Vessel Formation 269 Specific Manipulation of Tumor Angiogenesis Gene 270 Infertility Treatment for Women Discovered 270 Blocking Angiogenesis Signaling From Inside Cell May Lead to Serious Health Issues 271 New Ways for Endometriosis Treatment 273 Targeting Heparan Sulfate Inhibits Cancer Growth 274 Antifungal Drug Stops Blood Vessel Growth 274 Endorepellin and its Role in Halting Blood Vessels from Forming in Cancer 275 New Angiogenesis Discovery May Facilitate Fight against Cancer Growth 276 Cancer Stem Cells and Brain Tumor Therapy 278 MicroRNAs and Angiogenesis 278 V. CORPORATE DIRECTORY 280 VI. PATENTS INFORMATION 311
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.